{
    "2019-05-23": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Reports Data on Asthma Drug, Update from Annual Meet",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Asthma Drug",
                        "Annual Meet"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Tilray Stock Still Hasnâ€™t Bottomed",
                "features": {
                    "keywords": [
                        "Tilray",
                        "Stock",
                        "Bottomed"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Alphabet to Aid Pharma Giants Enhance Clinical Trial Process",
                "features": {
                    "keywords": [
                        "Alphabet",
                        "Pharma Giants",
                        "Clinical Trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis CEO says data quality, lagging innovation crimp China M&A",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "data quality",
                        "China M&A"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "(Re)Focusing Big Pharma: Novartis CEO Vasant Narasimhan with Jim Cramer at Healthy Returns",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "Big Pharma",
                        "Healthy Returns"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "After IFM buy, Novartis looks to more early stage biotech M&A",
                "features": {
                    "keywords": [
                        "Novartis",
                        "IFM buy",
                        "early stage",
                        "biotech M&A"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis CEO sees China M&A hampered by data, regulatory standards",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "China M&A",
                        "regulatory standards"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis CEO sees chance to accelerate profit margin target",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "profit margin",
                        "accelerate"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis has 25 blockbusters in the pipeline: CEO",
                "features": {
                    "keywords": [
                        "Novartis",
                        "blockbusters",
                        "pipeline",
                        "CEO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}